tiprankstipranks

Apexigen initiated with a Buy at EF Hutton

EF Hutton analyst Tony Butler initiated coverage of Apexigen with a Buy rating and $8 price target. The "recently de-SPACed" biotech is developing sotigalimab as an orthogonal immunoactivating therapy in combination with immune checkpoint inhibitors and chemotherapy against a number of cancer indications, Butler tells investors.

Confident Investing Starts Here:

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on APGN:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue